Industrial Bread Composition: Potential Implications for Patients with Inflammatory Bowel Disease
- PMID: 40647225
- PMCID: PMC12252189
- DOI: 10.3390/nu17132120
Industrial Bread Composition: Potential Implications for Patients with Inflammatory Bowel Disease
Abstract
Background: Ultra-processed food (UPF) intake, particularly that of industrial breads rich in food additives (FAs) like emulsifiers, has been linked to higher risk of inflammatory bowel diseases (IBD). Here, we screened the ingredients and FAs used in the bread industry and reviewed their potential biological effects. Methods: We consecutively screened breads available at supermarket and health food store chains in Israel. Bread products were analyzed by dietitians and categorized into three categories based on their composition: low processed (traditional ingredients), medium processed (additives like malt and fibers), and highly processed (FAs like emulsifiers and preservatives). We conducted a literature review to explore the links between the identified FAs, microbial composition and intestinal inflammation. Results: Of the 233 breads screened, 195 (84%) were highly processed, 9 (4%) medium-processed and 29 (12%) low-processed. We identified 37 different FAs and ingredients used. Most breads contained preservatives-189 (81%), and emulsifiers-178 (76%). Calcium propionate (E-282) was the most prevalent preservative present in 112 (48%) breads, while sodium-stearoyl-2-lactylate (SSL-E-481) was the most prevalent emulsifier present in 86 (37%) breads. The literature review revealed that 19 (51%) FAs used in the bread industry were associated with the exacerbation of inflammation or gut microbiome dysbiosis by increasing cytokine production and adversely affecting microbial composition. Conclusions: Most of the available breads in Israel are highly processed, containing FAs that may mediate intestinal inflammation. Low-processed breads are available and may be more recommended to patients with IBD. Further understanding of the role of FAs in IBD etiology may guide dietary recommendations.
Keywords: emulsifiers; food additives (FAs); inflammatory bowel disease (IBD); microbiome; preservatives; ultra-processed foods (UPFs).
Conflict of interest statement
These authors disclose the following: Lihi Godny: Takeda, Ferring, Altman; Tamar Pfeffer-Gik: Janssen, Danone, Altman; Henit Yanai: Pfizer, Abbvie, Janssen, Takeda, Bristol Myers Squibb, Eli-Lilly; Iris Dotan: Abbvie, Arena, Gilead/Galapagos, Genentech/Roche, Athos, Janssen, Pfizer, Takeda, Altman research, Celgene/BMS, Celltrion, Eli-Lilly, Dr. Falk Pharma, Ferring, Sandoz, and Harp diagnostics. The remaining authors disclose no conflicts.
Figures
References
-
- Ng S.C., Shi H.Y., Hamidi N., Underwood F.E., Tang W., Benchimol E.I., Panaccione R., Ghosh S., Wu J.C.Y., Chan F.K.L., et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies. Lancet. 2017;390:2769–2778. doi: 10.1016/S0140-6736(17)32448-0. - DOI - PubMed
-
- Wang R., Li Z., Liu S., Zhang D. Global, regional and national burden of inflammatory bowel disease in 204 countries and territories from 1990 to 2019: A systematic analysis based on the Global Burden of Disease Study 2019. BMJ Open. 2023;13:e065186. doi: 10.1136/bmjopen-2022-065186. - DOI - PMC - PubMed
-
- Alatab S., Sepanlou S.G., Ikuta K., Vahedi H., Bisignano C., Safiri S., Sadeghi A., Nixon M.R., Abdoli A., Abolhassani H., et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol. Hepatol. 2020;5:17–30. doi: 10.1016/S2468-1253(19)30333-4. - DOI - PMC - PubMed
-
- Narula N., Wong E.C.L., Dehghan M., Mente A., Rangarajan S., Lanas F., Lopez-Jaramillo P., Rohatgi P., Lakshmi P.V.M., Varma R.P., et al. Association of ultra-processed food intake with risk of inflammatory bowel disease: Prospective cohort study. BMJ. 2021;374:n1554. doi: 10.1136/bmj.n1554. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
